Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accumulated Expenses (2016 - 2018)

Historic Accumulated Expenses for Vanda Pharmaceuticals (VNDA) over the last 10 years, with Q1 2018 value amounting to $4.4 million.

  • Vanda Pharmaceuticals' Accumulated Expenses fell 8546.57% to $4.4 million in Q1 2018 from the same period last year, while for Mar 2018 it was $4.4 million, marking a year-over-year decrease of 8546.57%. This contributed to the annual value of $5.3 million for FY2017, which is 8440.1% down from last year.
  • As of Q1 2018, Vanda Pharmaceuticals' Accumulated Expenses stood at $4.4 million, which was down 8546.57% from $5.3 million recorded in Q4 2017.
  • In the past 5 years, Vanda Pharmaceuticals' Accumulated Expenses ranged from a high of $43.6 million in Q2 2015 and a low of $602000.0 during Q4 2014
  • Its 5-year average for Accumulated Expenses is $22.9 million, with a median of $30.1 million in 2015.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Accumulated Expenses crashed by 8837.84% in 2014, and later soared by 580531.56% in 2015.
  • Over the past 5 years, Vanda Pharmaceuticals' Accumulated Expenses (Quarter) stood at $602000.0 in 2014, then soared by 5805.32% to $35.6 million in 2015, then dropped by 4.01% to $34.1 million in 2016, then plummeted by 84.4% to $5.3 million in 2017, then dropped by 18.24% to $4.4 million in 2018.
  • Its Accumulated Expenses was $4.4 million in Q1 2018, compared to $5.3 million in Q4 2017 and $25.6 million in Q3 2017.